|
Mutation Information
|
Mutation Site
|
M250V |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Combined Mutation
|
rt.M250V+rt.T184I+rt.M204I+rt.A181S |
|
Genotype/Subtype
|
C |
|
Relevant Drug
|
entecavir (ETV) |
|
Country
|
China |
Literature Information
|
PubMed PMID
|
32569703
|
|
Disease
|
Chronic hepatitis B
|
|
Published Year
|
2020 |
|
Journal
|
Antiviral research |
|
Title
|
Hepatitis B virus mutation pattern rtA181S+T184I+M204I may contribute to multidrug resistance in clinical practice: Analysis of a large cohort of Chinese patients. |
|
Author
|
Chen R,Liu Y,Luo D,Si L,Huang B,Wang J,Li X,Cheng F,Xu D,Duan C |
|
Evidence
|
Specifically, rtM204I (95%) and rtA181S + T184I + M204I (5%) mutants were detected in sample A3 at 17 months; rtA181S + T184I + M204I (90%), rtA181S + T184I + M204V (5%), and rtA181S + T184I + M204I + M250V (5%) were detected in sample A4, along with virological breakthrough (VBT), at 24 months, and rtA181S + T184I + M204I (95%) and rtA181S + T184I + M204V (5%) in sample A5, along with a sustained higher level of HBV DNA, at 43 months.
|
|
|
HBV Mutation Detail Information